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HOMELESSNESS AND HEPATITIS C: RISK FACTORS AND TREATMENT 
STEVEN C. GOICOECHEA 
ABSTRACT 
 Hepatitis C is a public health crisis in both developing and developed countries. 
Direct acting antiviral therapies have revolutionized the fight against Hepatitis C, making 
the worldwide eradication of the disease feasible. However, screening and access to care 
for vulnerable patients – especially for patients experiencing homelessness – are lacking. 
Homelessness exacerbates the effects of Hepatitis C, leading to poor health outcomes for 
individual patients and high costs for health providers and taxpayers. One potential 
solution is investing in affordable housing and the housing first model that provide the 
stability needed to address both acute and chronic health conditions, including Hepatitis 
C. Partnerships between patients and providers facilitated by supportive housing can 
benefit individual outcomes and decrease the financial and social costs to communities. 
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INTRODUCTION 
 Homelessness poses a major public health crisis because of the poor living 
conditions and exposure to communicable diseases that people face during housing 
insecurity. With over 100 million people homeless across the world, homelessness 
requires specific clinical practices to address the multiple healthcare challenges that are 
exacerbated by the lack of housing (Beijer et al., 2012). Within the United States, current 
data suggests that 500,000-650,000 individuals are homeless at a given time; many of 
these people live in shelters, but 39% are estimated to live on the streets (Beijer et al., 
2012; Desmond and Gershenson, 2017).). Shelters provide a bed, food, and emergency 
medical care, but individuals face health risks both on the street and in shelters. 
 Many people avoid shelters due to violence there, close proximity with others that 
increases the spread of disease, and anxiety about living in a shelter (Wallace et al., 
2017). Living on the streets further increases malnutrition, physical violence, and 
communicable diseases while also decreasing access to medical care (Gubits et al., 2016). 
Increased risk of infectious disease is a major health concern for people living in 
homelessness. 
 
Infectious Disease and Homelessness 
 Of the three most prevalent infectious diseases that occur in the homeless – 
tuberculosis (TB), hepatitis C virus (HCV), and human immunodeficiency virus (HIV) – 
HCV has the highest prevalence (percentage of people who have the disease) in homeless 
populations in the United States (US) with a four-times greater rate of infection than the 
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general population (Beijer et al., 2012). Although TB and HIV have greater prevalence 
ratios in the homeless versus the general population, the sheer number of HCV infections 
is greater. In 2012, the prevalence of these infectious diseases across the world ranged 
from 0.2-7.7% for TB, 3.9-36.2% for HCV, and 0.3-21.1% for HIV infection (Beijer et 
al., 2012). 
 HIV, HCV, and TB have different routes of transmission and risk factors. As seen 
in Table 1, HIV is a sexually transmitted infection (STI), HCV is blood-borne, and TB is 
airborne (Badiaga et al., 2008). The transmission route determines the risk factors of each 
infection. Drug behavioral risks are present for each disease, sexual behavioral risks 
affect HIV and HCV, and sleeping in shelters increases the risk of TB due to close 
proximity. While these diseases often coinfect (Mo et al., 2014), this paper will focus on 
the risk factors, pathology, and treatment of HCV. 
 
Table 1. Infectious Diseases and Risk Factors Associated with Homelessness. HIV, 
HCV, and TB have different routes of transmission and risk factors, though there are 
overlaps in risk factors and frequent coinfection. Badiaga et al., 2008. 
Specific infection Transmission route Risk factors 
HIV STI Sexual and drug behavioral 
risks 
HCV Blood-borne Sexual and drug behavioral 
risks, HIV infection 
TB Airborne Sleeping in shelters, drug 
behavioral risks, 
malnutrition, HIV infection 
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Hepatitis C: Global to Domestic Scale 
 HCV is a major health concern across the world in both developing and 
developed countries. An estimated 185 million people worldwide – 2.8% of the global 
population – have been infected with HCV (Mohd Hanafiah et al., 2013) and of those 
people infected with HCV, the World Health Organization (WHO) estimates that 130–
150 million individuals are chronically infected (World Health Organization, 2017). 
North Africa, East Asia, and the Middle East have the highest prevalence of HCV 
estimated at more than 3.5% (Negro and Alberti, 2011). Global mortality due to HCV 
infection is approximately 700,000 people per year (Global Burden of Disease, 2013). 
From the global to domestic scale, HCV is a major public health concern in the United 
States. 
 The Centers for Disease Control and Prevention (CDC) estimates that there are 
29,700 new cases of HCV diagnosed per year, and this number is increasing (Center for 
Disease Control and Prevention, 2013). HCV is the leading cause of liver disease and 
liver cancer in the United States (Beiser et al., 2017). In the US, the number of deaths due 
to HCV surpassed those due to HIV infection in 2007 and there were a total of 19,368 
deaths caused by HCV in 2013 (Ly et al., 2012). Within the United States in 2010, the 
prevalence of HCV was 1% corresponding to 2.7 million chronically infected people 
(Denniston et al., 2014). As seen in Figure 1, the estimated prevalence of HCV infection 
based on anti-HCV and HCV RNA screening has decreased from 1988 to 2010 
(Denniston et al., 2014). However, there remain many infected individuals and more who 
are potentially undiagnosed. In most countries the proportion of undiagnosed, infected 
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patients is around 50% (Tomaszewski et al., 2012). Like other infectious diseases, rates 
of HCV infection are higher in socioeconomically and medically vulnerable populations. 
 
 
Figure 1. Estimated HCV Infection Rates in the United States. The estimated 
prevalence of HCV infection based on anti-HCV and HCV RNA has decreased from 
1988 to 2010. Infected persons reported in millions. Figure taken from Denniston et al., 
2014. 
 
High Risk Populations 
 Veterans, injection drug users, prisoners, and homeless individuals have higher 
rates of HCV infection (Beiser et al., 2017). In developed countries, the most significant 
risk factor is intravenous (IV) drug use due to contaminated needles, which leads to 60% 
of newly diagnosed cases (Wiessing et al., 2008). In addition, men who have sex with 
men (MSM) have a higher risk of infection (Wandeler et al., 2012). Homeless individuals 
face increased risk of developing chronic HCV and its complications due to the living 
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conditions in shelters and on streets as well as poor access to healthcare and follow-up 
services (Gubits et al., 2016). Among homeless individuals, the risk of HCV infection 
further increases with injection drug use and age. Lesser risk factors include alcohol and 
non-injectable drug abuse (Nyamathi et al., 2002). 
 People living in homelessness are at high risk for malnutrition, violence, and 
communicable diseases. Additionally, many people suffer from mental health disorders 
and substance abuse (Gubits et al., 2016). Living on the streets increases the risk of HCV 
infection while reducing access to essential healthcare (Stahre et al., 2011). Importantly, 
the association of HCV and injection drug use leads to high levels of social stigma 
against patients with the disease. Dr. Jane Megan Northrop’s interviews with patients 
diagnosed with HCV described destabilized self-identity and damaged self-esteem. In 
addition, these patients reported breaches in confidentiality, moral assumptions, and 
unwarranted fears in a medical setting (Northrop, 2017). The stigma associated with 
HCV can deter patients from seeking care. 
 Although there have been improved cure rates for HCV in the US, there are two 
major reasons why HCV will continue to be a public health concern. First, over 75% of 
infected adults are ‘baby boomers’, people born between 1945 and 1965 (Centers for 
Disease Control and Prevention, 2017). Thus, the burden of HCV will significantly 
increase over the next decade. Second, HCV has a low diagnosis rate, which may lead to 
an underestimation of total cases. Many people remain untreated because of the 
substantial barriers to treatment: insufficient screening, deficient linkage to care, and high 
treatment costs (Economic Intelligence Unit, 2017). Individuals with HCV can be 
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asymptomatic for decades, but they can still spread the disease (Santantonio et al., 2008). 
With the large number of infected patients and underestimation of total cases, HCV 
promises to put a large burden on the healthcare system. 
 The advent of direct acting antivirals (DAAs) has revolutionized the treatment of 
HCV (specific drugs and indications will be covered later in the current paper). While the 
eradication of the HCV is hypothetically possible with these new drugs, barriers still exist 
in screening, diagnosis, and care management; this is especially true for vulnerable 
patients living in homelessness. To understand how the treatment of HCV has been 
revolutionized with new drugs, as well as future challenges, the current paper will next 
review the characteristics, pathology, and clinical features and HCV. 
 
HCV Viral Particle, Genomics, and Life Cycle 
 HCV is relatively new to human knowledge and the scientific understanding of 
the virus has increased in recent decades. Figure 2 outlines the advancements in diagnosis 
and treatment of HCV from the isolation of HCV in 1989 to present day. In the 1970’s, 
Harvey J. Alter and his collaborators identified a non-A and non-B Hepatitis that was 
later isolated by the Chiron Corporation in 1989 and identified as Hepatitis C. The 1990’s 
witnessed the introduction of interferon (IFN) treatment, wide blood screening, and 
genotype classification (Goossens et al., 2016). The scope of the HCV public health crisis 
in the US became clear in 2007 when the number of deaths due to HCV surpassed those 
due to HIV infection (Ly et al., 2012). Finally, the first DAAs were approved in 2011 and 
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have since revolutionized treatment. The scientific breakthroughs in the past 4 decades 
arose from an understanding of the HCV viral particle, genomics, and life cycle. 
 
 
 
Figure 2. Timeline of HCV Discoveries and Treatments. From the isolation of HCV in 
1989 to present day, there have been advancements in diagnosis and treatment. HCV 
(Hepatitis C virus), HIV (human immunodeficiency virus), IFN-α (interferon-alpha), IL 
(interleukin), NS (non-structural), peg-IFN (pegylated interferon), SNP (single nucleotide 
polymorphism). Figure taken from Gossenns et al., 2016. 
 
The HCV Particle 
 Understanding the HCV particle, genome, and life cycle has contributed to the 
development of new drugs that target specific steps in viral replication. The enveloped, 
positive strand RNA virus belongs to the Flaviviridae family of viruses in the 
Hepacivirus genus. It is spherical with a diameter of 60-75 nm in cell culture 
(Gastaminza et al., 2010) and 40-80 nm in infected patients (Bradley et al., 1985). In an 
infected patient, the virus is composed of a icosahedral capsid containing a positive-
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sense, single-stranded RNA genome, an envelope originated from host cell membranes, 
and two viral glycoproteins: envelope proteins, E1 and E2. In addition, Figure 3 shows 
the apolipoproteins and core protein that form the viral particle (Goossens et al., 2016). 
 
Figure 3. The HCV Particle. The main features of the HCV particle are the envelope, 
envelope glycoproteins (E1 and E2), apolipoproteins, capsid, core proteins, and the RNA 
genome. Figure taken from Goossens et al., 2016. 
 
HCV Genomics 
 The HCV RNA genome is 9.6 kb in length with 5’ and 3’ untranslated regions 
(UTR) (Choo et al., 1991). Figure 4 outlines the HCV genome and associated proteins 
(specific functions of HCV proteins will be covered in the next section). The 5’UTR’s 
secondary structure contains four separate stem-loops called internal ribosome entry sites 
(IRES) that permit the cap-independent translation of the HCV RNA (Fraser et al., 2007). 
The 3’UTR contains a variable region, a poly-U/UC region, and 3’X region. The 
functions of the 3’UTR region are uncertain, but the 3’UTR may assist translation by 
relocating host translation machinery from the 3’ to the 5’ end of viral RNA (Bai et al., 
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2013). 
 Outside of the UTR, the HCV RNA contains two open reading frames (ORF). 
The large ORF encodes the HCV polyprotein, while the alternative ORF produces a 
singular F protein (Xu et al., 2001). The F protein is hypothesized to be involved in 
immune evasion (Komurian-Pradel et al., 2004). A major reason that scientists have 
encountered great difficulty in creating a HCV vaccine is the high variability of the virus. 
 
	
Figure 4. Map of the HCV Genome and Associated Proteins. The HCV genome 
includes the 5’UTR (contains the IRES), the 3’UTR (contains a variable region, a poly-
U/UC region, and 3’X region), the alternative ORF, and the large ORF that encodes the 
HCV polyprotein. Figure taken from Abdel-Hakeem et al., 2014. 
 
 HCV exists as 7 different genotypes that are subdivided into more than 60 
subtypes (Smith et al., 2014). Furthermore, the virus has a high rate of mutation and 
circulates within a single patient as related variants called “quasispecies.” Simmonds et 
al. estimated that strains from different HCV genotypes share a similarity of between 67-
69%. Furthermore, within subtypes 75-80% of nucleotides are the same based on 
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nucleotide homology analysis of the non-structural (NS) 5 region of the HCV genome 
(Simmonds et al., 2005). That is, there is considerable homology between HCV 
genotypes, but there is enough variability to require different genotyping and treatments, 
which will be covered later in the current paper. 
 Messina et al. carried out a large retrospective literature analysis in 2015 that 
demonstrated the prevalence of the 7 HCV genotypes (Messina et al., 2015). Genotype 1 
is most common (42%) followed by genotype 3 (30%). Genotypes 2, 4, and 6 together 
correspond to 23% and genotype 5 represents less than 1%. Lastly, Genotype 7 has been 
reported in only a few patients to date (Murphy et al., 2015; Murphy et al., 2017). Despite 
differences between HCV genotypes, they share components of the HCV genome, 
particle, and life cycle. The genome of HCV leads to a unique life cycle in the human 
body that explains its pathophysiology. 
 
HCV Life Cycle 
 This section will explore how HCV particles travel and proliferate in the body. 
HCV travels in blood in the form of lipoviro-particles (LVP), which are surrounded by 
components of low-density lipoproteins (LDL) and very low density lipoproteins 
(VLDL): apolipoproteins E and B and triglycerides (Andre et al., 2002). Because HCV 
particles use receptors associated with lipid uptake, LVP formation likely assists with 
HCV entry into host cells. In addition, lipoproteins surrounding HCV particles may 
protect from antibody recognition, helping HCV particles circumvent host defenses and 
proliferate (Andre et al., 2002). The virus has a limited tropism that causes it to primarily 
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infect hepatocytes; this explains the liver disorders caused by HCV infection. Figure 5 
highlights the 7 steps of the HCV life cycle: attachment, entry, uncoating, RNA 
translation and polyprotein maturation, RNA replication, particle assembly of lipid 
droplets, and release. 
 First, HCV particles 1) attach to host hepatocytes. The particles attach to LDL 
receptors (LDLR), scavenger receptor class B type 1 (SR-B1), and glycosaminoglycans 
on host cell membranes (Agnello et al., 1999; Scarselli et al., 2002). The interaction 
between HCV with SR-B1 then causes a change in the conformation of viral envelope 
glycoprotein E2, which causes binding of E2 to CD81 of the tetraspanin family of 
proteins (Bartosch et al., 2005). Once bound to CD81, HCV forms a complex with tight 
junction proteins (e.g. occludin and claudin-1) that trigger clathrin-mediated endocytosis 
into the host cell. The newly formed endosome has a low pH that triggers conformational 
changes of the E1 glycoprotein that lead to membrane fusion and capsid release. This 
completes the second step of the HCV life cycle: 2) entry into the host cell. 
 Next, the HCV particle undergoes 3) uncoating that releases the viral RNA inside 
the host cell (Farquhar et al., 2012), leading the way for viral translation and replication. 
HCV RNA is then 4) translated to produce viral proteins. Once inside the cell, HCV is 
treated as mRNA by the host’s cellular machinery and directly translated. Cellular 
ribosomes recognize the IRES at the 5’UTR and produce a polyprotein, which is then 
cleaved by host and viral proteases. The host proteases include signal peptidase and 
signal peptide peptidase; the viral proteases are NS2-NS3 and NS3-NS4 (Goossens et al., 
2016). These proteases cleave the polyprotein into 10 distinct proteins, including 
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structural and non-structural proteins, which are outlined in Table 2. Translation and 
maturation of viral proteins occur at the endoplasmic reticulum (ER) of the host cell 
(Goossens el al., 2016). 
 Several host and viral factors can modulate HCV translation. A human 
autoantigen, La, has been shown to facilitate ribosome assembly during initiation of 
translation (Izumi et al., 2004). Another host factor, miR-122, is a microRNA that helps 
activate translation by targeting two sites upstream of the HCV IRES (Jopling et al., 
2005; Roberts et al., 2011). Viral factors that modulate HCV translation include the NS2, 
NS3, NS4A, and NS4B proteins. Through initiation and modulation of translation, HCV 
and the host machinery produce abundant viral proteins. 
 Once enough viral proteins are produced, there is a switch from RNA translation 
to 5) RNA replication. Although this switch is poorly understood, Ray and Das 
hypothesize that the antagonistic effects of La and NS3 on translation could cause the 
switch from replication to replication (La activates translation while NS3 inhibits it) (Ray 
and Das, 2011). The viral RNA-dependent-RNA polymerase, NS5B, carries out RNA 
replication (She et al., 2008) in a structure called the membranous web. The web is a 
unique membrane structure that is induced by the virus (Egger et al., 2002). NS5B 
replicates the positive-sense RNA strand into a negative-sense strand intermediate; the 
negative-sense strand intermediate then acts as a template for the genomic strand 
(Goossens et al., 2016). Regulation is completed by both viral and host proteins. 
However, there are high mutation rates in the HCV genome because NS5B lacks 
proofreading. 
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 Next, there is a two-step process for the 6) assembly of lipid particles that contain 
HCV proteins and RNA. This process is integrally linked to lipid metabolism. First, the 
core HCV protein moves from the ER membrane to cytoplasmic organelles called lipid 
droplets (McLauchlan et al., 2002). The HCV RNA in the membranous web also moves 
to the lipid droplets once the NS5A protein coats the droplets (Masaki et al., 2008). 
Secondly, the NS2 protein forms the viral capsid, the protein shell of the virus. The viral 
capsids migrate to the ER lumen and acquire the viral envelope by budding of the ER 
membrane. Assembly and budding occurs at sites anchored by HVC glycoproteins E1 
and E2 (Popescu et al., 2011). 
 Lastly, the newly formed lipid particles are 7) released from host cells via 
exocytosis as LVPs (Gastaminza et al., 2006). They mature throughout the VLDL 
secretory pathway while associated with lipoproteins. Again, HCV has limited tropism, 
primarily infecting hepatocytes. Through the HCV life cycle, viral particles enter 
hepatocytes in order to multiply HCV proteins and RNA through host and viral 
machinery to then infect other hepatocytes. 
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Table 2. Hepatitis C Virus Proteins and Main Functions. There are both structural and 
non-structural proteins that perform various functions in the viral life cycle. Goossens et 
al., 2016. 
HCV Protein Main Function 
Structural 
Core Capsid protein 
E1 Fusion of viral particle to host cellular membranes 
E2 Attachment to the host cell 
Non-Structural 
p7 Formation of ion channel in endoplasmic reticulum membrane 
NS2 Protease: cleavage at the NS2/3 site 
NS3 Protease: cleavage at the NS3/4A, NS4A/B, NS4B/5A, NS5A/B sites 
NS4A Helicase (viral replication) 
NS4B Cofactor of NS3 
NS5A Formation of membranous web (viral replication) 
NS5B RNA-dependent-RNA-polymerase (replication of viral genome) 
 
 There are various structural and non-structural viral proteins that work in 
conjunction with host factors to carry out the HCV life cycle as seen in Table 2. Among 
the structural proteins, the core protein forms the capsid that contains the HCV genome 
while E1 and E2 allow the viral particle to fuse to the cellular membrane and attach to the 
host cell, respectively. The non-structural proteins perform viral translation, replication, 
and assembly alongside host factors. 
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 In summary, the HCV life cycle is closely linked to lipid metabolism; HCV 
travels in blood in the form of LVPs, which are surrounded by components of LDLs and 
VLDLs (Andre et al., 2002). The limited tropism leads to primary infection of 
hepatocytes. The HCV lifecycle targets hepatocytes through 7 steps: attachment, entry, 
uncoating, RNA translation and polyprotein maturation, RNA replication, particle 
assembly of lipid droplets, and release (Figure 5). The life cycle of HCV explains the 
pathophysiology and clinical features of infection. 
 
 
Figure 5. The HCV Life Cycle. The HCV lifecycle targets hepatocytes through 7 steps: 
attachment, entry, uncoating, RNA translation and polyprotein maturation, RNA 
replication, particle assembly of lipid droplets, and release. Figure taken from Goossens 
et al., 2016. 
 
 
HCV Pathophysiology 
 The liver synthesizes lipoproteins and is therefore integrally linked to the HCV 
life cycle that depends on formation of LVPs. Thus, hepatocytes are the major target of 
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HCV infection. Additionally, the immune response plays a large role in the 
pathophysiology of HCV infection. This next section will outline the host immune 
response and the basis for the use of interferon (IFN) drugs for the treatment of HCV. 
 As part of the innate immune system, infected cells use pathogen recognition 
receptors (PRRs) to recognize pathogen-associated molecular patterns (PAMPs) 
contained in pathogens, including components of the HCV particle and genome. During 
HCV infection, the antiviral state starts when hepatocytes recognize genomic structures 
specific to HCV via Toll-like receptor-3 (TLR-3) and retinoic acid-inducible gene-I 
(RIG-I) (Saito et al., 2008). Once these PRRs bind to a viral component, they initiate a 
cascade that eventually makes cytokines. Cytokines then activate the janus kinase/signal 
transducer and activator of transcription (Jak/STAT) signaling pathway which leads to 
transcription of interferon stimulated genes (ISGs) for host defense (Saito et al., 2008). 
 HCV interferes with the interferon response at multiple steps: 1) blocking the 
TLR-3 and RIG-1 pathways (Li et al., 2005; Foy et al., 2003) and the Jak/STAT pathway 
(Lin et al., 2006; Bode et al., 2003) as well as 2) interfering with ISGs (Taylor et al., 
1999). Thus, HCV can inhibit the host antiviral state. In addition, inhibition of dendritic 
cells and natural killer cells may lead to chronic infection (Jinushi et al., 2004). Dendritic 
cells produce cytokines and present antigens to prepare the adaptive immune response, 
while natural killer cells kill infected cells by recognizing down-regulated major 
histocompatibility complex class 1 (MHC-1) and viral signals. 
 In the adaptive immune system, T cells and B cells play a part against HCV. 
CD4+ (helper) T cells stimulate T and B cell production and activate macrophages. 
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CD8+ (cytotoxic) T cells kill infected host cells. B cells produce antibodies that 
neutralize viral antigens. While antibodies usually have little effect against the virus 
(Pestka et al., 2007), T cells are integral to the antiviral response (Thime et al., 2002). It 
is difficult to use T cells and antibodies as early diagnostic markers, however, because 
they are only detectable 5-9 weeks and 8-20 weeks after infection, respectively 
(Logyinoff et al., 2004). Ultimately, the innate and adaptive immune responses 
exacerbate HCV infection. 
 Figure 6 outlines the host response and viral evasion during HCV infection. 
Section A shows the host immune response. First, infected cells use PRRs to recognize 
PAMPs contained in the HCV particle and genome. The cells then start signal cascades to 
produce cytokines that trigger the host response. IFN signaling, dendritic cells, and 
natural killer cells combat the virus and kill infected cells. This innate immune response 
prepares the adaptive immune response: T cells and B cells. Section B shows the several 
mechanisms that HCV uses to evade the host response. During the innate immune 
response, HCV inhibits host cellular recognition of PAMPS, production of IFN, and 
ability to block viral replication. During the adaptive response, HCV inhibits T-cells and 
mutates so that antibodies are ineffective. Evasion of the host immune system and 
subsequent replication ultimately lead to HCV infection and the clinical features 
associated with the disease. 
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Figure 6. Host Immune Response and HCV Evasion. A: HCV induces the innate 
immune system response – interferon signaling, dendritic cells, and natural killer cells. 
This prepares the adaptive immune response – CD4+ and CD8+ T cells and B cells. B: 
HCV has mechanisms to undermine the immune response and establish chronic infection. 
Figure taken from Goossens et al., 2016. 
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HCV Clinical Features 
 HCV infection has different clinical manifestations associated with acute and 
chronic states. Acute HCV infection is generally asymptomatic, though a patient can 
experience mild, unspecific symptoms including dyspepsia (upper abdominal 
discomfort), fever, and jaundice (Santantonio et al., 2008). The first clinically detectable 
sign of HCV infection is elevated alanine aminotransferase (ALT) 4-12 weeks after 
infection. Spontaneous recovery can occur 3 months after initial infection, but most 
patients progress to chronic infection (Thein et al., 2008). 
 Clinicians define chronic HCV infection by detectable HCV RNA levels for more 
than 6 months after initial infection. An estimated 55-85% of patients progress from acute 
to chronic infection (Gerlach et al., 2003). Chronic HCV is characterized by liver fibrosis 
that eventually leads to cirrhosis. Fibrosis is the accumulation of extracellular matrix 
(ECM) caused by overproduction of ECM proteins as the liver heals itself from viral-
induced inflammation; cirrhosis causes reduced blood flow, which leads to loss of 
hepatocyte function and portal hypertension (Seeff et al., 2002). 
 Importantly, the natural progression of the disease is highly variable between 
infected patients. HCV genotype 3 has been associated with increased rate of fibrosis 
progression (Bochud et al., 2009) and hepatocellular carcinoma (HCC) (Nkontchou et al., 
2011) as well as decreased response to non-IFN antiviral treatment (Goossens et al., 
2014). In addition, sex and age play a role in disease progression with males and older 
individuals experiencing faster rates of disease progression (Leandro et al., 2006; Rüeger 
et al., 2015). Alcohol use and HIV co-infection also accelerate disease progression and 
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fibrosis (Wiley et al., 1998; Thein et al., 2008). Because of the inconspicuous nature of 
early HCV infection, there is a low threshold for testing (Santantonio et al., 2008). Left 
unidentified and untreated, the virus can lead to complications within a few years or 
decades. 
 In the natural progression of HCV pathology, patients develop chronic infection 
and cirrhosis, which leads to further disease progression. HCV infection has primarily 
hepatic clinical manifestations, though there are also extrahepatic complications. One 
study estimated the prevalence of cirrhosis at 16% 20 years after infection (Thein et al, 
2008). However, estimates vary between studies and populations. Cirrhosis increases the 
risk of steatosis and HCC, leading to liver decompensation. Studies of patients with HCV 
and cirrhosis found that 40-86% develop steatosis (Asselah et al., 2006) and 7% of 
patients developed HCC after 5 years (Fattovich et al., 1997). Steatosis and HCC, as well 
as non-hepatic complications, are leading causes of death in patients with HCV infection. 
 
Steatosis (Fatty Liver Disease) 
 Chronic HCV infection causes steatosis, the accumulation of lipids in the 
cytoplasms of hepatocytes. As the liver loses function, steatosis is caused by increased 
lipid neogenesis (Waris et al., 2007), impaired lipid secretion (Perlemuter et al., 2002; 
Mirandola et al., 2006), impaired fatty acid oxidation in mitochondria (Yamaguchi et al., 
2005; Dharancy et al., 2005), and increased formation of lipid droplets (Clément et al., 
2011). Because HCV needs lipids to complete its life cycle, it is suggested that the virus 
benefits from accumulated lipids (Andre et al., 2002). 
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Hepatocellular Carcinoma 
 In developed countries, HCV infection is the main cause of HCC with 50-60% of 
patients with HCC infected with HCV (El-Serag, 2012). Furthermore, HCC is the major 
cause of death of HCV infected patients (Perz et al., 2006). HCC is mainly caused by 
chronic inflammation and cirrhosis (Simonetti et al., 1991). In addition, the insulin 
resistance and steatosis induced by HCV can lead to HCC (Hung et al., 2010; Ohata et 
al., 2003; Kurosaki et al., 2010). Even with the use of antiviral therapy, the risk of HCC 
can only be reduced, not eliminated in patients with advanced fibrosis. 
 
Non-hepatic Complications 
 HCV infection has both hepatic and non-hepatic clinical manifestations. Most 
patients with chronic HCV die from hepatic causes, although non-hepatic causes – 
especially renal and cardiovascular – are increased in HCV infected patients (Negro, 
2014). HCV infection can lead to increased cardiovascular risk (Negro et al., 2015), 
hematologic disorders including Hodgkin lymphoma (Giordano et al., 2007; Gisbert et 
al., 2003), possible link with type 2 diabetes (Goossens et al., 2014), dermatologic 
diseases (Gisbert et al., 2003), and neurologic complications in the peripheral nervous 
system (Gemignani et al., 2005) and central nervous system (Poynard et al., 2002; Forton 
et al., 2002; Schaefer et al., 2012). The next section will discuss the screening, diagnosis, 
and treatment of HCV to understand the challenges facing individual patients and public 
health efforts. 
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HCV Screening and Diagnosis 
 Despite the introduction of highly effective DAAs, poor rates of diagnosis and 
access to care have made the eradication of HCV challenging. In a 2001-2008 US-based 
cohort study of 30,140 patients, only half of those positive for HCV were aware of their 
HCV-positive status (Denniston et al., 2012). As discuss above, the asymptomatic initial 
phase of infection makes diagnosis difficult and thus increases the likelihood of chronic 
infection. In the fight against HCV, there is currently a solid understanding of the virus’ 
pathophysiology, diagnosis, and treatment. However, at the current time screening and 
access to care – especially for homeless and other vulnerable populations – are lacking. 
 
Screening 
 Screening for HCV is difficult due to the largely asymptomatic phase of early 
infection, compounded by the large number of people who are at risk. The CDC has 
recommended a one-time screening for baby boomers born between 1945-1965 because 
this age group has a five-times higher prevalence than other age groups (AASLD/IDSA, 
2015; Grebely et al., 2013; Smith et al., 2012). This decision was controversial because 
of evidence that suggests that risk factors in individuals are under-reported (Goossens et 
al., 2016). That is, it may be more beneficial to screen individuals based on risk factors as 
opposed to population-wide screenings. 
 European guidelines recommend screening individuals based on risk factors, 
although the CDC has adopted the population-wide screening (the US also endorses 
screenings based on risk factors, although less effort has been put into these screenings). 
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As seen in Table 3, recommendations for HCV screening cover a multitude of risk 
factors, including individuals in the baby boomer generation and behavior and exposures 
that increase contact with infected blood (AASLD/IDSA, 2015; Goossens et al., 2016). 
Early reports from insurance claims in the US show increased screening for baby 
boomers (AASLD/IDSA, 2015), but underdiagnosis remains a substantial challenge. 
 
Table 3. Recommendations for HCV Screening Based on Risk Factors in the United 
States. Recommendations for HCV screening include individuals in the baby boomer 
generation and individuals with increased exposure to blood-borne pathogens. 
AASLD/IDSA, 2015; Goossens et al., 2016. 
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Diagnosis 
 There are a variety of different HCV diagnostic tests that have a high accuracy. 
However, the asymptomatic phase of chronic HCV infection can limit early diagnosis. 
Current guidelines recommend that individuals who qualify for HCV testing should first 
be tested for HCV antibodies and then tested for confirmatory HCV RNA 
(AASLD/IDSA, 2015; EASL, 2015). If a patient qualifies for treatment, genotype testing 
is mandatory to dictate a specific antiviral therapy. This section will focus on specific 
diagnostic methods and highlight the importance of early testing. 
 
Assays: Serology 
 The most common initial screening is a third generation enzyme immunoassay 
(EIA) that detects structural and non-structural viral proteins (Goossens et al., 2016). 
EIAs detect antibodies that bind to viral antigens from four viral regions: NS3, NS4, 
NS5, and core. Serological assays are highly sensitive and specific (>99%). However, 
they lead to a substantial amount of false positive results in populations with low HCV 
prevalence (Alter et al., 2003). 
 
Assays: Rapid Antibody Testing 
 Rapid antibody testing has been made available due to the high demand for rapid 
on-site tests. Results are available 20-40 minutes after testing samples from venipuncture 
or finger-stick blood (Goossens et al., 2016). These tests have similar sensitivity and 
specificity to EIAs (Khuroo et al., 2015), but it is recommended that rapid testing is 
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followed-up with additional testing. Still, studies suggest that rapid tests could widen 
access to diagnostic tests for people at risk of HCV infection (Khuroo et al., 2015). 
 
Assays: HCV RNA Testing 
 Once an individual has tested positive for HCV antibodies, they are tested for 
confirmatory HCV RNA. Other indications for HCV RNA testing include 
immunocompromised patients, HCV exposure within the past 6 months, and patients 
undergoing antiviral therapy (AASLD/IDSA, 2015). There are both quantitative and 
qualitative HCV RNA tests; qualitative tests simply provide a ‘yes/no’ answer, while 
quantitative tests show the amount of HCV RNA. Importantly, qualitative tests have 
greater sensitivity (Goossens et al., 2016). After HCV antibodies and RNA have been 
confirmed, genotyping helps direct therapy. 
 
Genotyping HCV 
 HCV exists as 7 different genotypes that are subdivided into more than 60 
subtypes (Smith et al., 2014). Genotypes differ from one another by 31-33% of 
nucleotides and subtypes differ by 20-25% of nucleotides (Simmonds et al., 2005). 
Genotyping is essential for clinicians to accurately interpret prognosis and histology as 
well as select the proper course of treatment. Genotype 3 has a particularly different 
prognosis and histology (Goossens and Negro, 2014). Because genotype 1 is the most 
common (42% of cases), clinicians also distinguish between subtypes 1a and 1b (Murphy 
et al., 2017).  
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 There are multiple methods for HCV genotyping. The most accurate method is 
direct sequencing of the viral genome by phylogenic analysis, but this is not always 
practical in a clinical setting due to cost and time constraints (Goossens et al., 2016). 
More feasible clinical methods include sequencing the 5’UTR or using differential 
hybridization on the 5’UTR (Stuyver et al., 1996). Differentiating genotype 1 subtypes is 
very important for DAA therapy. Clinicians use a reverse hybridization assay for the 
5’UTR and core regions to distinguish subtypes 1a and 1b with 99% accuracy (Chevaliez 
et al., 2009). In addition to assays and genotyping, histology and non-invasive techniques 
can diagnose HCV infection. 
 
Liver Biopsy and Histology 
 A key component of disease management for HCV patients is assessing the stage 
of liver disease through invasive and non-invasive techniques. Liver biopsy allows 
clinicians to determine the degree of liver damage and stage of disease (fibrosis, 
cirrhosis, and HCC) through grading systems. The two most common grading systems 
are the Ishak and METAVIR (Ishak et al., 1995; Bedossa and Poynard, 1996). These 
grading systems assess the extent of portal fibrosis and formation of fibrotic septa. Liver 
biopsy can also determine additional hepatic conditions: iron deposits, fatty liver disease, 
and other indications of HCV disease progression. Histology also offers the ability to use 
specific stains to determine disease progression, but these results do not always agree 
with entire surgical samples (King et al., 2015; Bedossa et al., 2003). In addition, liver 
biopsy poses a risk to patients – severe complications were found in 0.57% of patients in 
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a prospective, nation-wide French study (Cadranel et al., 2000). The complications 
associated with liver biopsy give non-invasive techniques an advantage. 
 
Non-invasive Testing 
 Non-invasive testing with clinical markers can assess the degree of liver fibrosis. 
Diagnostic markers can be both direct (type IV collagen, pro-collagen) and indirect 
(platelet count, ratio of aspartate aminotransferase (AST) to alanine aminotransferase 
(ALT)) (Castera, 2012). The major advantage of non-invasive methods is the decreased 
risk to patients, but they have unreliable specificity (45-99%) and sensitivity (30-98%) 
(Castera, 2012). In addition, these methods are useful for advanced fibrosis and cirrhosis, 
but less reliable for early and intermediate disease progression. 
 Current diagnostic methods for HCV are variable in technique and accuracy, 
allowing clinicians to make reliable diagnoses of HCV infection and genotype. There are 
currently efforts to improve HCV screening so that patients can be diagnosed and 
connected with treatment. Now the paper will focus on the management and 
accompanying challenges of HCV antiviral therapy. 
 
HCV Treatment and Disease Management  
 The goal of antiviral therapy is to cure a patient of HCV to avoid complications 
such as cirrhosis, steatosis, and HCC. Cure of HCV is defined as sustained virological 
response (SVR): undetectable HCV RNA 24 weeks after completion of antiviral therapy. 
SVR is associated with reduced mortality and HCC (van der Meer et al., 2012). The 
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treatment of HCV has been revolutionized with the advent of DAA therapies that are 
highly tolerable and effective. However, increased efficacy is accompanied by high 
financial cost and the subsequently limited access to therapy for patients with chronic 
HCV infection. The increase in efficacy and cost has led to societal and ethical discussion 
of resource distribution (Girardin et al, 2015). 
 International guidelines recommend that all patients with chronic HCV infection 
should be considered for antiviral therapy (EASL, 2015; AASLD/IDSA, 2015). However, 
treatment is also prioritized based on the degree of fibrosis, liver failure, extrahepatic 
manifestations, and risk of transmission due to limited funding and resources. Priority is 
also given to patients with coinfections of hepatitis B virus (HBV) or HIV as well as 
individuals who pose a high risk of viral transmission (IDU, MSM, incarcerated 
individuals, etc.) (EASL, 2015; AASLD/IDSA, 2015). There are no absolute 
contraindications to DAAs, although each clinical case should be assessed, especially for 
patients with limited life expectancy or those undergoing antiretroviral therapy for HIV. 
There are two main classes of drugs: IFNs and DAAs. 
 
Interferon and Ribavirin 
 Before the introduction of DAAs in 2011, treatment of HCV was based on a 
combination a peg-IFN-α and ribavirin. The combination treatment leads to 40-50% SVR 
in patients with genotype 1 and 4, and higher rates of SVR in genotypes 2, 3, 5, and 6 
(EASL, 2011; Manns, 2006). The treatment also has extensive side effects that affect 
kidney function, cognitive symptoms, and flu-like symptoms. Largely due to these side 
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effects, 10-20% of patients have discontinuation or interruption of treatment (Manns, 
2006). Homelessness and other risk factors exacerbate discontinuation because successful 
treatment requires regular visits and stable life style. For this reason, DAAs are favored to 
increase SVR and compliance. 
 
Direct Acting Antivirals 
 DAAs target multiple steps in the HCV life cycle and are used in combination to 
avoid resistance in the viral population (Mohsen and Levy, 2016). Two drugs, sofobuvir 
(Sovaldi) and simeprevir (Olysio) have increased cure rates to over 90% and shortened 
treatment from 48 to 12 weeks since being release in 2013 (Beiser et al., 2017). 
Additionally, side effects have also been decreased in many patients compared to IFN 
drugs (Beiser et al., 2017). A brief overview of DAA classes: 
 
1) NS3/4A protease inhibitors 
 In 2011, the first DAAS were approved. Two first generation NS3/4A protease 
inhibitors (PIs), telaprevir and boceprevir, were approved for use in genotype 1 infection 
along with peg-IFN-α and ribavirin. This treatment led to SVR rates of 70% (Jacobson et 
al., 2011; Poordad et al., 2011). These drugs inhibit the HCV NS3/4A serine protease, 
thus blocking the viral replication process. However, the first generation drugs had a 
burdensome side effect profile, leading to the approval of a second generation NS3/4A 
PI, simeprevir, in 2014. Simpevir is better tolerated alongside peg-IFN-α and ribavirin. 
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2) NS5A inhibitors 
 NS5A inhibitors inhibit the formation of membranous structures essential for 
HCV replication and assembly by inhibiting the NS5A protein. The drugs, including 
ledipasvir, daclatasvir, and ombitasvir, are effective against multiple genotypes, but HCV 
can develop resistance relatively easily to them. Each drug is used in different 
combinations with NS3/4A PIs and other NS5A inhibitors (EASL, 2015; AASLD/IDSA, 
2015). 
 
3) NS5B inhibitors 
 Similar to NS5A inhibitors, NS5B inhibitors block HCV replication by inhibiting 
the RNA-dependent RNA polymerase, NS5B. The NS5B protein is highly conserved, 
making NS5B inhibitors effective across genotypes. This class of drug is further divided 
into two classes: nucleoside PIs and non-nucleoside PIs. The major nucleoside PI is 
sofosbuvir. It is primarily excreted by the kidneys and should be avoided in patients with 
renal impairment. Non-nucleoside PI, including dasabuvir, are less effective and have a 
lower barrier to resistance (EASL, 2015; AASLD/IDSA, 2015). 
 An estimated 55-85% of patients infected with HCV progress from acute to 
chronic infection (Gerlach et al., 2003). For this reason, early treatment is paramount. 
Each genotype of HCV has different treatment regimes outlined by EASL and 
ASSLD/IDSA (EASL, 2015; AASLD/IDSA, 2015). Importantly, therapies are constantly 
evolving with new drugs and research. These therapies can be used to treat vulnerable 
patients, but there is debate over the best methods of treatment and distribution of care. 
	 31	
Despite higher costs, DAAs are more cost effective when considering the health benefit 
and social improvement (Wong et al., 2017). 
 HCV is a serious public health concern in the United States and across the world. 
The life cycle and pathology of HCV cause liver disease and the virus is the leading 
cause of liver disease in the United States (Beiser et al., 2017). While the infectious 
disease poses a risk across demographics, it has a four-times greater rate of infection 
among patients experiencing homelessness (Beijer et al., 2012). The scientific 
understanding of HCV has led to effective screening, diagnosis, and treatment. However, 
there remain challenges to treating the disease, especially in vulnerable patients. 
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RESULTS 
 Over the course of the last 4 decades, there have been substantial breakthroughs in 
understanding and treating HCV. As the current paper has outlined, medical providers 
currently have effective methods to diagnose and treat HCV. The current paper will 
transition to focus on methods to improve screening and treatment for vulnerable 
populations, with special focus dedicated to housing for people experiencing 
homelessness. 
 The homeless population in the United States is diverse; each individual should be 
assessed for other factors: age, injection drug use, mental health, sexual orientation, 
veteran status, criminal history, etc. Thus, a patient’s housing status should not be the 
only criteria to assess risk and treatment. Homeless individuals face increased risk of 
developing chronic HCV and its complications due to the living conditions in shelters 
and on streets as well as poor access to healthcare and follow-up services. Two major 
concerns hamper effective care for people experiencing homelessness: cost effective care 
and housing to improve follow-up care. 
 
Cost Effectiveness of Treatment 
 Untreated chronic HCV has indirect costs that compound the deleterious health 
effects to individuals and economic costs to society. For example, chronic disease can 
lead to lower work productivity and absenteeism (Su et al., 2010). In addition, increased 
treatment duration, hospitalizations, and emergency room visits put a toll on healthcare 
providers and financial spending. Homeless patients overuse emergency medical services 
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before being turned back to the streets, which are largely a source of their poor health and 
economic burden (Parsell et al., 2017). The indirect economic benefits of treating chronic 
HCV bolster the cost-effectiveness of treatment that uses efficacious drugs in most 
patient populations (Estes et al., 2015). 
 Cost-effectiveness analysis offers an avenue to determine the most effective 
allocation of resources with the ultimate goal of maximizing quality of life for a given 
patient population (Detsky et al., 1990). An analysis by Wong et al. of economic 
outcomes in patients using DAA vs. peg-IFN treatments showed that DAA therapy was 
economically favorable in increasing quality-adjusted life years (QALYs) – a measure of 
quality and quantity of life for individual patients (Wong et al., 2017). Thus, DAAs are 
more cost effective when considering individual patient outcomes in addition to indirect 
economic benefits. However, there remains a problem of ensuring compliance to DAAs 
for people struggling to find stable housing, food, and transportation. 
 
Housing and Health 
 The effect of homelessness on health is multidimensional and requires 
multidimensional solutions. The crux of this solution is the integration of medical care 
and social services, including supportive housing, social services, and care coordination. 
Integrating healthcare and housing is effective for healthcare outcomes for homeless 
individuals (Parsell et al., 2017). By providing housing, healthcare providers substantially 
decrease barriers to care and increase quality of life. Housing, then, is a social 
determinant of health and an opportunity to improve healthcare outcomes in patients. 
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 Low-income families have experienced income stagnation in the last 20 years, but 
housing costs have continued to climb (Sandel and Desmond, 2017). Simultaneously, 
public aid has not expanded, leaving 3 out of 4 households that qualify for public 
assistance without it. Lack of affordable housing was the leading cause of homelessness 
in the 25 largest US cities in 2013 (Hunger and Homelessness Survey, 2014). In 2014, 
6.6 million people in the US were paying over 50% of their income toward housing, 
representing a 27% increase from 2007 (Kottke et al., 2017). Estimates in 2017 show that 
2.8 million renting households are at risk of eviction and more than 500,000 people are 
homeless on a given night (Desmond and Gershenson, 2017). The American housing 
crisis has pushed many households out of housing and left even more with less money for 
healthcare. 
 There is a cyclical pattern between homelessness and deterioration of wellbeing. 
Adults experiencing homelessness or housing insecurity are more likely to experience 
trauma, substance use, domestic violence, and psychological distress (Gubits et al., 
2016). Furthermore, children experiencing homelessness have more difficulty in school 
and display more antisocial behavior (Gubits et al., 2016). In the United States, homeless 
people die almost four-times faster than housed people (O’Connell, 2005); housing-
insecure people are more likely to not seek medical care due to cost (Stahre et al., 2011). 
 The “housing first” model places people facing housing insecurity into permanent 
housing without mandatory substance treatment or other services. Housing individuals 
promotes healthy behaviors and access to care (Dunn, 2000; Tsemberis et al., 2004) with 
the goal of improving patient outcomes and decreasing high-cost medical care (Larimer 
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et al., 2009). Indeed, reviews of the housing first model have shown decreased 
emergency room visits and hospitalizations, especially for patients with dual diagnoses, 
mental health conditions, and substance use disorders (Lim et al., 2018). 
 Efforts to improve housing have good value compared to other clinical services 
(Ly et al., 2015). Housing improves management of chronic conditions, decreases 
emergency department visits (Shumway et al., 2008), reduces exposure to toxic 
chemicals, stress, and physical harm (Jelleyman et al., 2008; Sandel et al., 2015), and 
increases worker productivity (Healy, 1971). Case studies of 3 homeless individuals 
showed decreased hospital visits and costs to hospitals after they were housed (Stafford 
and Wood, 2017). These financial benefits extend to larger healthcare organizations, 
including hospital systems and Medicaid. 
 One example of a hospital system that has integrated housing and medical care is 
Mount Sinai Hospital in New York. Through a partnership with the Two Shades of Green 
housing program, the hospital provides affordable housing that is energy efficient and 
safe (Two Shades of Green, 2018). This stable housing has reduced the risk of asthma 
and minimized exposures to toxic chemicals. Similar supported housing programs have 
effectively reduced health disparities by concurrently addressing medical spending, 
housing costs, and social determinants of health (Sandel and Desmond, 2017). 
 A study by Lim et al. showed that supportive housing was associated with 
Medicaid savings, especially for patients with low coverage and high expenditures (Lim 
et al., 2018). Because almost 50% of Medicaid spending comes from 4% of enrollees 
(Sommers et al., 2006), supported housing offers an established method to decrease 
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expenditures by vulnerable patients. These 4% of enrollees include patients who are 
elderly or housing insecure and those who have chronic medical conditions, mental 
illness, or substance use disorders. 
 There has been increasing interest in the housing first model to combat the high 
cost of Medicaid that increased from $210 billion in 2000 to $408 billion in 2011 (Lim et 
al., 2018). Lim et al. found that putting high-risk individuals (individuals with chronic 
homelessness and mental illness or a dual diagnosis of mental illness and substance use 
disorder) into supportive housing saved an average of $9526 per individual 2 years after 
being housed (Lim et al., 2018). The researchers explain that the savings arise from 
decreased emergency room visits, shorter and fewer inpatient visits, and increased care 
management enabled by housing. Supportive housing offers system-wide economic 
benefits and improved healthcare outcomes that could be extended to patients with HCV. 
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DISCUSSION 
 Homelessness and healthcare equity are fundamentally related. People 
experiencing homelessness have shorter life expectancy, higher morbidity, and rely more 
heavily on hospitals for acute services (Gubits et al., 2016; Jelleyman et al., 2008; Sandel 
et al., 2015; Shumway et al., 2008). Homelessness is a social determinant of health, but it 
is also the result of diverse social and economic factors. That is, homelessness cannot be 
diagnosed or treated as a single social determinant. Instead, healthcare providers and 
policy makers must recognize the multitude of circumstances and behaviors that drive 
homelessness: lack of affordable housing, drug use, mental health, unemployment, poor 
health, trauma, etc. Furthermore, housing does not simply affect health unidirectionally. 
Rather, homelessness and poor health affect one another in a negative cycle (Sandel and 
Desmond, 2017; Stafford and Wood, 2017). For this reason, it is paramount to 
incorporate wrap-around social services and wellness interventions alongside housing. 
 Addressing the integral relationship between the housing crisis and health will 
require new approaches to housing-based care. Firstly, hospitals and healthcare systems 
will need new partnerships between both non-profit and for-profit organizations: 
government leaders, affordable housing developers, community boards, and investors. 
Hospitals could invest more heavily in affordable housing and disperse risk in shared-
investing efforts – for example, the Healthy Neighborhoods Equity Fund – that bridge 
hospitals, government leaders, banks, and philanthropists (Sandel and Desmond, 2017). 
Secondly, combining social services and medical care with housing could maximize 
investment (Sandel and Desmond, 2017; Stafford and Wood, 2017). 
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 In addition to providing the housing first model and affordable housing, another 
possible solution is street-based medical outreach. There are effective healthcare 
interventions in the US that are based on the streets or in the shelters (Badiaga et al., 
2008). Health professionals can have a major impact by treating homeless patients on the 
streets or in shelters because many patients have substantial barriers to care or simply do 
not seek care. Both strategies – housing and outreach – complement one another to 
improve care for vulnerable patients. 
 
Future Challenges in Treating HCV 
 The advent of efficacious antiviral drugs has made the global eradication of HVC 
feasible. Recent public health interventions in Georgia show the potential of widespread 
eradication the virus (Mitruka et al., 2015). However, models predict that current 
treatment uptake is insufficient to decrease future morbidity and mortality (Razavi et al., 
2014). The peak of the HCV health burden is expected to hit most developed countries in 
2030 (Wedemeyer et al., 2014). To reduce mortality by 90% by 2030, treatment uptake 
must increase four-fold in many of these countries (Wedemeyer et al., 2014). This would 
require national health efforts that would better connect patients to general practitioners 
for diagnosis and treatment. There is not currently a vaccine for HCV, although efforts to 
devise one are underway. 
 With the great strides in medical diagnosis and treatment, there need to be equal 
improvements in screening, treatment distribution, and medical follow-up. DAA therapy 
will make a relatively small impact in communities and the world if fewer patients are 
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identified; in most countries the proportion of undiagnosed, infected patients is around 
50% (Tomaszewski et al., 2012). Furthermore, population and risk-based screenings have 
proven unsuccessful in most countries (Tomaszewski et al., 2012). Researchers have 
instead proposed birth cohort screening. This strategy may especially be effective in the 
US where baby boomers account for 27% of the population and upwards of 75% of HCV 
infections (Smith et al., 2012). There are significant barriers to treatment – especially in 
medically vulnerable populations like individuals experiencing homelessness – that pose 
serious risk to overcoming this global health crisis. 
 A significant challenge of DAAs is their market price. The high cost of these 
efficacious drugs forces healthcare authorities to allocate resources to patients with 
advanced or complicated cases (Wong et al., 2017). Allocating funds will inherently 
affect the net health impact for a population with some patients benefitting and others 
suffering. This leads to ethical conflict, especially when considering high-risk patients 
who face barriers to care. While housing offers an avenue to increased cost effectiveness 
for homeless patients, there is strong backlash against investing in housing (Estes et al., 
2015; Wong et al., 2017).	
 With the 2018 Fiscal Year budget cutting housing dollars (National Low Income 
Housing Coalition, 2017), it is important that hospital systems, healthcare plans, and 
private and public organizations invest in housing to improve health outcomes. In 
addition, physicians and other healthcare professionals can advocate to clinics, hospitals, 
and healthcare plans to decrease housing insecurity and economic costs as well as 
improve health outcomes for patients experiencing homelessness. 
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 The investment in affordable housing is difficult to measure strictly by profits or 
saved costs. Thus, investment should also be reflected in the overall health of 
communities. Housing provides the stability needed to address both acute and chronic 
health conditions, including HCV. This stability enables patients and providers to 
improve health in partnership, instead of relying on short-term, repeated interventions 
that overburden hospitals and emergency departments. Indeed, the partnership between 
patients and providers facilitated by supportive housing will benefit individual outcomes 
and the broader financial and social costs to communities. 
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